Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Leases: 2014-2016

  • Viridian Therapeutics, Inc.\DE's Current Leases fell 95.45% to $4,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $4,000, marking a year-over-year decrease of 95.45%. This contributed to the annual value of $4,000 for FY2016, which is 95.45% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Current Leases of $4,000 as of Q4 2016, which was down 95.45% from $88,000 recorded in Q4 2015.
  • Viridian Therapeutics, Inc.\DE's 5-year Current Leases high stood at $88,000 for Q4 2015, and its period low was $4,000 during Q4 2016.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Current Leases had a median value of $80,000 in 2014 and averaged $57,333.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Current Leases climbed by 10.00% in 2015 and then slumped by 95.45% in 2016.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's Current Leases (Quarterly) stood at $80,000 in 2014, then grew by 10.00% to $88,000 in 2015, then tumbled by 95.45% to $4,000 in 2016.
  • Its Current Leases was $4,000 in Q4 2016, compared to $88,000 in Q4 2015 and $80,000 in Q4 2014.